newsfilter
← Latest News
GlobeNewswire·

Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25

BIXT
  • Bioxytran Inc. highlighted a new book by Dr. Avraham Mayevsky titled "Physiological Mapping of the Cerebral Cortex in Neuropathology" published by Springer.
  • The book introduces "Physiological Mapping," a methodology for real-time monitoring of tissue metabolism & oxygenation in vivo using FDA-cleared devices licensed exclusively to Bioxytran.
  • The research focuses on rat brain models involving ischemic stroke, epilepsy, traumatic brain injury, hypoxia, & related neurological conditions.
  • Monitoring techniques assess mitochondrial NADH redox state alongside cerebral blood flow, tissue oxygen, extracellular potassium, DC potential, & electrocorticography.
  • CEO David Platt stated these physiological mapping approaches may complement the future evaluation of BXT-25, an investigational oxygen therapeutic designed to facilitate oxygen diffusion into hypoxic tissues.
  • The book explores metabolic oscillations in ischemic brain tissue, the role of nitric oxide, interactions between epilepsy & partial ischemia, & effects of hyperoxia, anesthesia, & age-related ischemic injury.
  • BXT-25 is an investigational heme-based oxygen-transport therapeutic intended for early-stage stroke treatment to transport oxygen into tissues with impaired blood flow.
  • Bioxytran believes advanced monitoring tools will support translational research, study design, & indication selection for therapies targeting tissue hypoxia & impaired oxygen utilization.
  • Dr. Mayevsky has collaborated with Bioxytran's scientific network for several decades, a partnership the company considers vital to its development strategy.
  • The book targets neurologists, neurosurgeons, anesthesiologists, & researchers focused on cerebral metabolism & oxygen physiology.
  • BXT-25 is not approved by the U.S. Food & Drug Administration for any indication.
  • Bioxytran Inc. is a clinical-stage biotechnology company developing carbohydrate-based therapeutics & oxygen therapeutics for viral diseases, fibrosis, hypoxia-related disorders, & inflammation.